Author | Derick H. M. Lau, MD, PhD

Articles

Adjuvant Treatment of Stage IB NSCLC: The Problem of Stage Subset Heterogeneity

April 30, 2008

Stage IB non–small-cell lung carcinoma (NSCLC) represents a subset of early-stage, resectable NSCLC, usually treated with curative intent, but with historically modest 5-year survival rates ranging from 40% to 67% with surgical resection alone.[1,2] Disappointingly, modern adjuvant chemotherapy trials including stage IB patients have shown little evidence of chemotherapeutic benefit.

Gemcitabine in Combination With New Platinum Compounds: An Update

March 03, 2001

ByDavid. R. Gandara, MD

Martin J. Edelman, MD

Primo N. Lara, Jr, MD

Derick H. M. Lau, MD, PhD

Combinations of gemcitabine (Gemzar) with cisplatin (Platinol) are among the most active new chemotherapy regimens developed for advanced non-small-cell lung cancer. Carboplatin (Paraplatin) is a platinum analog

Evolution of Combined Modality Therapy for Stage III Non–Small-Cell Lung Cancer

July 02, 2000

ByDavid R. Gandara, MD

Martin Edelman, MD

Primo N. Lara, Jr, MD

Derick H. M. Lau, MD, PhD

Peter Roberts, MD

Bryan R. Leigh, MD

A number of randomized clinical trials and meta-analyses now support the conclusion that combined modality regimens that include cisplatin (Platinol)-based chemotherapy improve survival in stage III non–small-cell lung

Gemcitabine/Carboplatin Combination Regimens: Importance of Dose Schedule

July 01, 2000

ByDavid R. Gandara, MD

Derick H. M. Lau, MD, PhD

Primo N. Lara, Jr, MD

Martin J. Edelman, MD

Platinum compounds, either cisplatin (Platinol) or carboplatin (Paraplatin), in combination with a number of new chemotherapeutic agents, have demonstrated improved response or survival compared to cisplatin alone or older